Pages that link to "Q34507966"

The following pages link to MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. (Q34507966):

Displayed 16 items.

• First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response (Q33777877) ‎ (← links)
• Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment (Q35787908) ‎ (← links)
• Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme (Q36525099) ‎ (← links)
• Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas (Q37409721) ‎ (← links)
• The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline (Q38623610) ‎ (← links)
• Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. (Q38623612) ‎ (← links)
• Curcumin Reactivates Silenced Tumor Suppressor Gene RARβ by Reducing DNA Methylation (Q38874057) ‎ (← links)
• Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase (Q39229754) ‎ (← links)
• Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss (Q42376082) ‎ (← links)
• IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas (Q48618352) ‎ (← links)
• MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors (Q48686096) ‎ (← links)
• Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide (Q48863873) ‎ (← links)
• MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis (Q48873373) ‎ (← links)
• CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression. (Q50709265) ‎ (← links)
• Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression. (Q55459936) ‎ (← links)
• TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. (Q55461118) ‎ (← links)